ACR Appropriateness Criteria® rectal cancer: metastatic disease at presentation.
暂无分享,去创建一个
A. Koong | K. Goodman | W. Suh | T. Hong | S. Jabbour | P. Das | M. Abdel-Wahab | N. Azad | S. Milgrom | M. Rodriguez-Bigas | A. Konski | Rachit Kumar | W. Small | W. Jones | J. Herman | C. R. Thomas | A. Blackstock | P. Das
[1] T. Pawlik,et al. What are patients' expectations about the effects of chemotherapy for advanced cancer? , 2014, Journal of the American College of Surgeons.
[2] Tushar C. Barot,et al. Yttrium-90 Microsphere-selective Internal Radiation Therapy With Chemotherapy (Chemo-SIRT) for Colorectal Cancer Liver Metastases: An In Vivo Double-Arm–Controlled Phase II Trial , 2013, American journal of clinical oncology.
[3] K. Havenga,et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Michael Scholz,et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). , 2013 .
[5] C. Hammill,et al. Laparoscopic radiofrequency ablation for the management of colorectal liver metastases: 10‐year experience , 2013, Journal of surgical oncology.
[6] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[7] Luigi Solbiati,et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. , 2012, Radiology.
[8] E. Van Cutsem,et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Tassone,et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. , 2012, Oncology reports.
[10] T. Chua,et al. Two Decades of Experience with Hepatic Cryotherapy for Advanced Colorectal Metastases , 2012, Annals of Surgical Oncology.
[11] R. Parks,et al. Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983) , 2012, Annals of surgery.
[12] J. Kamps,et al. Angiogenesis in Synchronous and Metachronous Colorectal Liver Metastases: The Liver as a Permissive Soil , 2012, Annals of surgery.
[13] Geerard L Beets,et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Dejong,et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[15] D. Lambrechts,et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet.
[16] Joon-Oh Park,et al. Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer , 2011, Radiation oncology.
[17] P. Weatherall,et al. Phase I Dose-Escalation Study of Stereotactic Body Radiotherapy in Patients With Hepatic Metastases , 2011, Annals of Surgical Oncology.
[18] N. Tebbutt,et al. Changing Management and Survival in Patients With Stage IV Colorectal Cancer , 2011, Diseases of the colon and rectum.
[19] D. Fraker,et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol , 2011, Cancer.
[20] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Koong,et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. , 2010, International journal of radiation oncology, biology, physics.
[22] E. Van Cutsem,et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Curley,et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? , 2010, Journal of the American College of Surgeons.
[24] N. Kemeny,et al. Metastatic Colorectal Cancer: From Improved Survival to Potential Cure , 2010, Oncology.
[25] Christophe Hennequin,et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. J. Haas,et al. Impact of portal vein embolization on long‐term survival of patients with primarily unresectable colorectal liver metastases , 2010, The British journal of surgery.
[27] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[28] C. Bokemeyer,et al. 6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status , 2009 .
[29] L. Schwartz,et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] L. Gaspar,et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Figer,et al. Is There a Survival Benefit to Neoadjuvant Versus Adjuvant Chemotherapy, Combined with Surgery for Resectable Colorectal Liver Metastases? , 2009, World Journal of Surgery.
[32] C. Bokemeyer,et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Seta Shahin,et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[35] Thomas Gruenberger,et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.
[36] P. Tekkis,et al. Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients , 2008, Annals of surgery.
[37] E. Berber,et al. Survival After Radiofrequency Ablation of Colorectal Liver Metastases: 10-Year Experience , 2007, Annals of surgery.
[38] W. Scheithauer,et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC) , 2007 .
[39] W. Scheithauer,et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer , 2007 .
[40] L. Crinò,et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] M. Gonen,et al. Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study , 2007, Annals of Surgical Oncology.
[42] D. Sargent,et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] J. Berlin,et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab , 2005, Journal of surgical oncology.
[44] Rainer Fietkau,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.
[45] Bernard Paule,et al. Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.
[46] Fábio Guilherme Campos,et al. Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-term Results , 2004, Annals of surgery.
[47] I. Endo,et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. , 2004, Surgery.
[48] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[49] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[50] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Robert C. G. Martin,et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. , 2003, Journal of the American College of Surgeons.
[52] E Harrison,et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[55] H. Wieand,et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. , 1994, The New England journal of medicine.
[56] K. Eichler,et al. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. , 2009, Radiology.
[57] W. Franklin,et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] O. Goletti,et al. Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer , 2006, Annals of Surgical Oncology.